SCHEMBL26042822

SCHEMBL26042822

CN1CCC(N2CCN(C(=O)CCC3CN(C)C3)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
HIF1A Q16665 1/20 0.47
GNAI3 P08754 3/20 0.45
GNAO1 P09471 3/20 0.45
GNAI1 P63096 3/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HSD11B1 P28845 1/20 0.44
ATM Q13315 1/20 0.43
TP53 P04637 1/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
F2R P25116 1/20 0.43
ACHE P22303 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25955527 0.91 KMT2A (0.57) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL24352355 0.90 KMT2A (0.48) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL24204530 0.86 KMT2A (0.49) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL26042821 0.85 L3MBTL3 (0.47) KMT2AMEN1ALDH1A1KDM4EGNAI3
SCHEMBL24802116 0.85 MEN1 (0.51) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL24351560 0.85 MEN1 (0.51) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL25074011 0.83 GNAI3 (0.54) KMT2AALDH1A1GNAI3GNAO1GNAI1
SCHEMBL25074352 0.83 GNAI3 (0.54) KMT2AALDH1A1GNAI3GNAO1GNAI1
SCHEMBL25074008 0.83 GNAI3 (0.54) KMT2AALDH1A1GNAI3GNAO1GNAI1
SCHEMBL24802123 0.82 GNAI3 (0.58) KMT2AMEN1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 KMT2A 2176/4885MEN1 3601/4885ALDH1A1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.